Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine면역원성과 반응성 간의 연관성: 보조제가 포함된 재조합 대상포진 백신에 대한 2개의 3상 연구의 사후 분석Clinical Trial Published on 2022-11-282023-06-01 Journal: The Journal of Infectious Diseases [Category] Fulltext, 대상포진, 두창, 수두, 홍역, [키워드] antibodies AS01 reactogenicity recombinant zoster vaccine T cells [DOI] 10.1093/infdis/jiab536 PMC 바로가기 [Article Type] Clinical Trial
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of AgeArticle Published on 2022-11-032022-11-15 Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 변종, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered administration Adults Adverse age assigned authority B.1.1.529 children circulating Cohort cohorts coronavirus coronavirus disease criteria determine development dose duration of follow-up Efficacy elicited evaluate evaluated event geometric mean concentration immune response incidence Infection injection median Month mRNA-1273 mRNA-1273 vaccine neutralizing antibody observer-blinded open label Part phase 3 trial Placebo placebo-controlled predominant Randomly reactogenicity receive Safe Secondary objective selected the vaccine Trial Vaccine variant Year [DOI] 10.1056/NEJMoa2209367 PMC 바로가기
Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunityArticle Published on 2022-11-012022-11-15 Journal: Annals of allergy, asthma & immunology : official [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] antibody Antibody Response Autoimmune clinical trial clinician Combination Comorbidities coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine criteria detectable Diagnosis Evidence Factor healthy controls immune immune dysregulation Immunity immunodeficiency immunogenic individuals literature Messenger RNA Patient performed reactogenicity response Safe Safety SARS-CoV-2 Serious Adverse Events subjects T cell response vaccination Vaccinations Vaccine [DOI] 10.1016/j.anai.2022.06.009 PMC 바로가기
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
‘Mix and Match’ vaccination: Is dengue next?Article Published on 2022-10-262022-11-15 Journal: Vaccine [Category] COVID19(2023년), SARS, 진단, [키워드] 'Mix and match' Antigen approach benefit boost breadth cellular Cellular responses Combination COVID-19 COVID-19 pandemic demonstrated Dengue dengue virus Dengvaxia dose effective Efficacy evaluated help Heterologous HIV homologous Human Humoral immunity Immunity immunization Impact Increased immunogenicity induce match overcome priming reactogenicity regimen reported response SARS-CoV-2 SARS-CoV-2 vaccine sequence severity significantly study participant T cell TAK-003 the vaccine Trial trials TV003 vaccination Vaccine Vaccines [DOI] 10.1016/j.vaccine.2022.09.007 PMC 바로가기
Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, PeruArticle Published on 2022-10-172022-11-15 Journal: PLoS ONE [Category] 진단, [키워드] administration ANCOVA anti-SARS-CoV-2 IgG antibody BBIBP-CorV BNT162b2 BNT162b2 vaccine booster conducted COVID-19 infection COVID-19 vaccine dose Elderly patient evaluated geometric geometric mean ratio HCW healthcare worker Heterologous heterologous vaccine homologous IgG IgG antibody IgG level immunized immunogenic immunogenicity increase in median mRNA vaccine National of BNT162b2 participant Pfizer produced prospective cohort study reactogenic reactogenicity regimen regressions Safe significantly Sinopharm two group vaccination Vaccine vaccine for COVID-19 was measured [DOI] 10.1371/journal.pone.0268419 PMC 바로가기
A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE networkArticle Published on 2022-10-082022-11-15 Journal: Trials [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ≥75 years. adaptive addition advanced age age Analysis Antibody titre benefit BNT162b2 BNT162b2 (Comirnaty®) booster booster dose changes in Clinical course collected concern conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine dose Endpoint enzyme-linked immunosorbent evaluate exploratory fourth dose humoral immune response immunosenescence include individual initial Intervention mRNA-1273 mRNA-1273 (Spikevax®) multicentre neutralising neutralising antibody titre Older Part Patient performed phase phase II primary endpoint protocol qPCR Quantitative randomisation randomised randomised controlled reactogenicity Research risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine secondary subgroup T cell response the primary endpoint Trial triggered vaccination Vaccine vaccine-induced immune response variants variants of concern VoC wild-type wild-type virus [DOI] 10.1186/s13063-022-06791-y PMC 바로가기
A Bivalent Omicron-Containing Booster Vaccine against Covid-19Article Published on 2022-10-062022-11-15 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome addition Administered Alpha B.1.1.529 binding antibody Bivalent booster booster dose Booster vaccine booster vaccines coronavirus dose Effectiveness elicited Exploratory analysis geometric mean titer group Infection Interim median time mRNA-1273 mRNA-1273 booster neutralizing antibody Neutralizing antibody response occurred other variant participant Participants reactogenicity responses against RNAs Safety SARS-CoV-2 SARS-COV-2 infection Vaccine variant Wuhan-Hu-1 [DOI] 10.1056/NEJMoa2208343 PMC 바로가기
Reactogenic sleepiness after COVID-19 vaccination. A hypothesis involving orexinergic system linked to inflammatory signalsReview article Published on 2022-10-012022-10-05 Journal: Sleep medicine [Category] COVID19(2023년), SARS, 바이오마커, [키워드] Activation addition adverse event Compliance Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Critical disease manifestation global healthcare Healthcare professional Hypothesis IL-1β Immunity IMPROVE INF-γ Inflammatory inflammatory signal inhibit innate immune system interactions knowledge mechanism morbidity and mortality Narcolepsy Neuron occur Orexin physiological pro-inflammatory cytokine reactogenic reactogenicity Regulation reported Research SARS-COV-2 infection Sickness Side effect Sleep Sleep disturbance Symptom TNF-α vaccination Vaccine while [DOI] 10.1016/j.sleep.2022.06.011 [Article Type] Review article
Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicityArticle Published on 2022-10-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-receptor-binding domain antibody Antibody titer binding antibody BNT162b2 booster dose ChAdOx1 comparable COVID-19 delta variant domain dose enrolled evaluated geometric geometric mean titer group groups HCW HCWs healthcare worker Heterologous heterologous vaccination homologous humoral immune response Humoral response immunogenicity induce Local Neutralizing antibody response Neutralizing antibody titer participant RBD reactogenicity reactogenicity profile reduced robust SARS-CoV-2 SARS-CoV-2 spike protein significantly higher systemic reactogenicity tolerable vaccination variant wild-type SARS-CoV-2 [DOI] 10.1016/j.cmi.2022.04.019 PMC 바로가기